Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of complement proteins as screening markers for colorectal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Early life body size, growth and risks of systemic lupus erythematosus - A large Danish observational cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Magnus Pedersen
  • Rikke Andersen
  • Peter Henrik Nørgaard
  • Søren Jacobsen
  • Peter Thielsen
  • Per thor Straten
  • Inge Marie Svane
Vis graf over relationer

Two patients were treated with immunotherapy for metastatic malignant melanoma (MM) despite suffering from systemic autoimmune disease, i.e., ulcerative colitis (UC) and Behcets disease (BD), respectively. Both patients benefitted from the treatment. The patient with UC achieved partial remission of all measurable parameters after treatment with Ipilimumab, while the patient with BD achieved a complete remission of MM after treatment with Interleukin-2 (IL-2) and Interferon-α (IFN-α). Moreover, no aggravation of symptoms related to the autoimmune diseases was seen during treatment, in contrast, clinical indications of improvement were observed. These two cases illustrate that the presence of autoimmune disease does not necessarily predict increased autoimmune toxicity in connection with immunotherapy. They also raise the question of whether autoimmune disease should continue to be an absolute exclusion criterion for treatment of MM with immunotherapy. Consequently, given the poor prognosis of refractory MM, immunotherapies need to be taken into consideration even in cases of autoimmune comorbidity due to the potential long-term benefit that these therapies offer to MM patients.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy
Vol/bind63
Udgave nummer12
Sider (fra-til)1341-6
Antal sider6
ISSN0340-7004
DOI
StatusUdgivet - dec. 2014

ID: 44852847